DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Modifying PEST for Psoriatic Arthritis Screening

Not Applicable

Recruiting

Conditions: Plaque Psoriasis
Psoriatic Arthritis

Interventions: Diagnostic Test: PEST Screening group

First Posted Date: 2024-04-24

Last Posted Date: 2025-03-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 502

Registration Number: NCT06382051

Locations: 🇨🇦
Novartis Investigative Site, Stoney Creek, Ontario, Canada

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Phase 1

Recruiting

Conditions: Metastatic Neuroendocrine Prostate Cancer

Interventions: Drug: [68Ga]Ga-PSMA-11
Drug: [68Ga]GA-DOTA-TATE
Drug: [68Ga]Ga-NeoB
Drug: [177Lu]Lu-PSMA-617
Drug: [177Lu]Lu-DOTA-TATE
Drug: [177Lu]Lu-NeoB
Drug: Gonadotropin-releasing hormone (GnRH) analogues
Drug: L-Lysine HCl-L-Arginine HCl, 2.5 %,
Drug: GnRH antagonists
Drug: Antiemetics & antinauseants
Drug: Metoclopramide

First Posted Date: 2024-04-23

Last Posted Date: 2025-04-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT06379217

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States
🇺🇸
Memorial Sloan Kettering Cancer Ctr, New York, New York, United States

and more 1 locations

A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers

Phase 1

Active, not recruiting

Conditions: Lung Cancer
Ovarian Cancer

Interventions: Drug: [68Ga]Ga-EVS459
Drug: [177Lu]Lu-EVS459

First Posted Date: 2024-04-19

Last Posted Date: 2025-02-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4

Registration Number: NCT06376253

Locations: 🇮🇱
Novartis Investigative Site, Tel Aviv, Israel

Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction

Phase 4

Recruiting

Conditions: Plaque, Atherosclerotic

Interventions: Drug: atorvastatin
Procedure: IVUS/OCT
Drug: inclisiran

First Posted Date: 2024-04-18

Last Posted Date: 2025-03-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 318

Registration Number: NCT06372925

Locations: 🇨🇳
Novartis Investigative Site, Harbin, Heilongjiang, China

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Recruiting

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Ofatumumab

First Posted Date: 2024-04-03

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT06345157

Locations: 🇮🇹
Novartis Investigative Site, Novara, Italy

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

Completed

Conditions: BRAF V600 Mutation Positive Melanoma

First Posted Date: 2024-03-29

Last Posted Date: 2024-03-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT06337617

Locations: 🇨🇳
Novartis, Shanghai, China

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

Phase 1

Recruiting

Conditions: Systemic Lupus Erythematosus, SLE

Interventions: Drug: PIT565

First Posted Date: 2024-03-28

Last Posted Date: 2025-04-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT06335979

Locations: 🇨🇭
Novartis Investigative Site, St Gallen, Switzerland

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

Phase 3

Recruiting

Conditions: Polymyalgia Rheumatica

Interventions: Biological: Secukinumab

First Posted Date: 2024-03-26

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT06331312

Locations: 🇺🇸
Orrin Troum MD and Medical Associates, Santa Monica, California, United States
🇺🇸
Millennium Clinical Trials, Westlake Village, California, United States
🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

and more 13 locations

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

Completed

Conditions: Breast Cancer

Interventions: Drug: First-line Ribociclib + endocrine therapy
Drug: First-line endocrine therapy
Drug: First-line chemtherapy

First Posted Date: 2024-03-15

Last Posted Date: 2025-03-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2615

Registration Number: NCT06311383

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Phase 2

Recruiting

Conditions: Systemic Lupus Erythematosus
Sjögrens Disease
Rheumatoid Arthritis

Interventions: Biological: VAY736 1ml PFS
Biological: VAY736 2ml AI
Biological: VAY736 2 ml PFS

First Posted Date: 2024-03-05

Last Posted Date: 2025-05-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 140

Registration Number: NCT06293365

Locations: 🇺🇸
Pinnacle Research Group Llc, Anniston, Alabama, United States
🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸
Advanced Medical Research, La Palma, California, United States

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy